Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Efficacy of Remdesivir in Coronavirus Disease 2019 (Covid-19): A Systematic Review



Roshanshad A1, 2 ; Kamalipour A2, 3 ; Ashraf MA1 ; Roshanshad R1 ; Jafari S4 ; Nazemi P5 ; Akbari M1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Department of MPH, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Department of Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, University of California, San Diego, CA, United States
  4. 4. Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Infectious Diseases, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Microbiology Published:2020

Abstract

Background and Objectives: Researchers all around the world are working hard to find an effective treatment for the new coronavirus 2019. We performed a comprehensive systematic review to investigate the latest clinical evidence on the efficacy and safety of treatment with Remdesivir in hospitalized patients with COVID-19. Materials and Methods: We performed a systematic search in Pubmed, Embase, Web of Science, Google scholar and MedRxiv for relevant observational and interventional studies. The outcomes measures were mortality rates, improvement rates, time to clinical improvement, all adverse event rates and severe adverse event rates. Results: Three randomized controlled trials and 2 cohort studies were included in our study. In the 2 cohort studies, patients received Remdesivir for 10 days. 2 RCTs evaluated 10-day efficacy of treatment with Remdesivir versus placebo group and the other RCT compared its 5-day regimen versus 10-day regimen. Visual inspection of the forest plots revealed that the efficacy of Remdesivir was not much different in reducing 28-day mortality versus 14-day mortality rates. Besides, 10-day treatment regimen overpowered 5-day treatment and placebo in decreasing time to clinical improvement. All adverse event rates did not have a significant difference; however, severe adverse event rate was lower in the 5-day Remdesivir group compared to the 10-day and placebo groups. Conclusion: 5-day course of Remdesivir therapy in COVID-19 patients is probably efficacious and safe, and patients with-out invasive mechanical ventilation benefit the most. Treatment can be extended to 10 days if satisfactory improvement is not seen by day 5. Most benefits from Remdesivir therapy take place in the first 14 days of the start of the treatment. © 2020, Tehran University of Medical Sciences. All rights reserved.
Other Related Docs
14. Therapeutic Potentials and Candidates for Covid-19, Iranian Journal of Science (2023)
25. Potential Therapeutic Options for Covid-19: An Update on Current Evidence, European Journal of Medical Research (2022)
27. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of Covid-19, Cardiovascular and Hematological Disorders - Drug Targets (2021)
28. Novel Therapeutic Approaches for Treatment of Covid-19, Journal of Molecular Medicine (2020)